Trial reportBMC oral health2026
A prospective, triple-blind, randomized controlled clinical trial evaluating the protective effect of P11-4 peptide on enamel demineralization during multibracket orthodontic treatment.
Trial report in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07664046 (A Three-arm Randomized Controlled Trial Evaluating the Effectiveness of Self- Assembling Peptide P11-4 in the Remineralization of Enamel Carious White Spot Lesions), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Three-arm Randomized Controlled Trial Evaluating the Effectiveness of Self- Assembling Peptide P11-4 in the Remineralization of Enamel Carious White Spot Lesions
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis prospective, triple-blind, randomized controlled clinical trial evaluated the additional caries-preventive effect of a self-assembling peptide (P11-4) gel with fluoride applied at home during multibracket (MB) orthodontic treatment in adolescents. PARTICIPANTS AND
methodsTwenty-five patients aged 11–17 years (mean age 14.5 years) were randomized to a test group (P11-4 gel including 900 ppm sodium monofluorophosphate) or a placebo group (900 ppm sodium monofluorophosphate gel without P11-4 gel). Participants applied the assigned gel twice weekly for 18 months. Caries development was assessed using the International Caries Detection and Assessment System (ICDAS) and quantitative light-induced fluorescence (QLF) at baseline (t0), and after 6 (t1), 12 (t2), and 18 months (t3) after baseline. Statistical analyses were performed using non-parametric tests (α = 0.05).
resultsAt 18 months, 7.2% of surfaces in the test group and 14.5% in the placebo group showed initial lesions (ICDAS 1 or 2; p < 0.0001). All QLF parameters showed significantly lower demineralization in the test group throughout the study (p < 0.0001). In the test group, QLF parameters at t3 were: ΔF = -0.91%, ΔFmax = -1.17% and ΔQ = -12.06%px. Corresponding values in the placebo group were: ΔF = -2.07%, ΔFmax = -2.75% and ΔQ = -36.31%px. Lesion volume (ΔQ) decreased over time in the test group, indicating remineralization. No adverse effects were observed.
conclusionRegular home use of P11-4 gel with fluoride reduced the development of enamel demineralization in adolescents with fixed appliances. Despite the small sample size and limited patient-level power, the findings indicate that P11-4 with fluoride can serve as a useful adjunct to established home-based preventive measures during orthodontic treatment. CLINICAL RELEVANCE: A biomimetic peptide gel with fluoride used at home can prevent development of initial caries lesions during orthodontic treatment and may benefit patients with limited oral hygiene or high caries risk. The study was conducted in accordance with the World Medical Association Declaration of Helsinki. The study protocol was reviewed and approved by the Ethics Committee of the Medical Faculty of the Philipps-University of Marburg, Germany (approval number 197/21, date of approval: 20 January 2022). The study protocol was registered in the German Clinical Trials Register: Trial registration number: DRKS00028048, date of registry: 07 February 2022). The study was conducted following the Good Clinical Practice standards and the General Data Protection Regulation (GDPR).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.